Deals
After being bought by Bain for $3.3 billion, Tanabe has reached a deal to sell its manufacturing unit and 17 products.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
BioCity, the pioneering life science incubator and business collective, has today announced investment in precision medicine biotech, Kinomica Ltd., via the Innovate UK Precision Medicine Investment Accelerator.
This week, Roche said it extended its tender-offer period for outstanding shares of Spark to Oct. 1 from Sept. 3.
TreeFrog Therapeutics, an expert stem cell company, announces that it has received close to €3M in non-dilutive funding from French and European programs.
MilliporeSigma has acquired all ownership rights to the ProcessPad™ platform from Simplyfeye Softwares Private Limited. The agreement includes the transfer of all copyrights and relevant intellectual property related to this software platform.
Acacia Pharma Group plc announces its unaudited interim results for the six-month period ended 30 June 2019.
Polyphor AG announced that the company will present at the 21st Annual H.C. Wainwright Global Investment Conference, taking place September 8-10, 2019 in New York City.
Late Wednesday, the company said it is looking to facilitate the sale of its business products in development, as well as its technology.
Biofidelity Ltd announces it has secured £0.75 million seed financing, following its formation earlier this year.
Polyphor AG focused on the discovery and development of immuno-oncology compounds and a new class of antibiotics, publishes today its financial results for the first half of 2019 and announces a realignment of the strategy.
Massachusetts Life Sciences Center awards funding to support early-stage growth across major sectors
MLSC’s Milestone Achievement Program awards more than $1.9 million to 10 companies representing all major life sciences sectors